Partial
Partially Aligned
Patient Risk:
Low
Summary
Some content aligns with the label (motion sickness prevention; patch delivers ~1 mg over 3 days; applies behind one ear; duration up to 3 days), but multiple claims about brand names/market availability are not addressed in the provided FDA label excerpts. Also, “transdermal patch ingredient is scopolamine (scopolamine hydrobromide)” is not explicitly supported in the supplied excerpts.
Category Scores
Accurate Statements
Scopolamine patches are used for motion sickness prevention.
Section 1 (INDICATIONS AND USAGE): “Scopolamine transdermal system is indicated in adults for prevention of… nausea and vomiting associated with motion sickness.”
In a patch dosage form, the ingredient is scopolamine (scopolamine hydrobromide).
Partially supported: the provided excerpts state scopolamine transdermal system formulation delivers scopolamine; however the explicit “scopolamine hydrobromide” phrasing is not present in the excerpts provided.
Unsupported Statements
Scopolamine skin patches are commonly sold under the brand name Transderm Scōp.
The provided label excerpts do not discuss brand availability or naming conventions by market.
Transderm Scōp is marketed by Rhodes Pharmaceuticals in some markets.
No manufacturer/marketing company or licensing-by-country information appears in the provided label excerpts.
Product availability of Transderm Scōp varies by country.
The provided label excerpts do not address country-by-country availability.
In the United States, Transderm Scōp is the best-known brand name for the scopolamine transdermal patch.
The provided label excerpts do not discuss comparative brand recognition.
Other markets may list different local brand names for scopolamine transdermal patches.
The provided label excerpts do not discuss alternative brand naming by market.
Transderm Scōp is the brand name most often associated with scopolamine used for motion sickness.
The provided label excerpts do not discuss brand association/frequency.
Contradictions
Important Omissions
The response does not mention label-required key dosing/administration instructions that would be material if asserting use details (e.g., apply at least 4 hours before effect is required; only one system at a time; do not cut; apply postauricular; discard displaced system; duration up to 3 days and replacement behind the other ear if longer).
Importance:
Moderate
The response does not mention important label safety warnings relevant to scopolamine patches (e.g., contraindication in angle closure glaucoma; acute angle closure glaucoma symptoms prompting removal; neuropsychiatric reactions such as hallucinations/confusion; blurred vision; urinary retention; MRI burn risk; post-removal withdrawal symptoms; avoidance in severe preeclampsia).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most claims are about branding/availability and do not directly change dosing or safety. However, the response includes an ingredient statement not fully supported by the provided excerpts and omits multiple safety and administration specifics that are materially relevant when discussing use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Label does not support brand/marketing/market-availability claims; ingredient phrasing (“scopolamine hydrobromide”) and any use-detail safety/administration statements are not adequately supported by provided excerpts.
Suggested Improvement
Limit claims to label-supported indications and dosing/administration or omit brand/availability statements not present in the provided label excerpts; when discussing patch use, include only those administration and safety elements directly supported by the provided FDA labeling text.